Reviva Pharmaceuticals (NASDAQ:RVPH) reported quarterly losses of $(0.57) per share which missed the analyst consensus estimate of $(0.10) by 455.88 percent. This is a 81.1 percent increase over losses of $(3.00) per share from the same period last year.